Table 2.
Previous lines of treatment per patient
| First line | Second line | Third line | Response to the previous line† | TTP‡ | |||
|---|---|---|---|---|---|---|---|
| Treatment* | Response | Treatment | Response | Treatment | Response | ||
| MATRix (4) | PD | PD | 0 | ||||
| MATRix (4) > ASCT > WBRT | CR | CR | 9 | ||||
| MTX-ARAC (3) | PD | PD | 0 | ||||
| R-MPV (3) > WBRT + ITT | CR | MATRix (4) > ASCT | CR | CR | 8 | ||
| R-MTX-ARAC (4) > WBRT | PD | PD | 0 | ||||
| R-MTX-ARAC (4) > ASCT | CR | CR | 2 | ||||
| R-MTX-ARAC (4) | PD | Resection | PD | PD | 0 | ||
| MTX-ARAC (2) > WBRT | CR | CR | 1 | ||||
| R-MTX (3) > WBRT | PR | TMZ (2) | PD | R (4) | PD | PD | 0 |
| R-MTX-ARAC (4) > ASCT | CR | WBRT | CR | CR | 3 | ||
| MATRix (4) | PD | WBRT | CR | CR | 2 | ||
| R-MTX-ARAC (3) + ITT | PD | R-ITX-VP16 (2) | PD | WBRT | CR | CR | 3 |
| MTX-TMZ (5) + ITT | CR | CR | 8 | ||||
| MATRix (4) > De-VIC | PD | PD | 0 | ||||
| MTX (17) | CR | R-TMZ (4) | PD | PD | 0 | ||
| MATRix (4) > ASCT | CR | CR | 27 | ||||
| MATRix (4) > ASCT | CR | CR | 84 | ||||
| MATRix (4) > ASCT > WBRT | PD | PD | 0 | ||||
| R-MTX-ARAC (4) | PD | PD | 0 | ||||
| MATRix (2) | PD | PD | 0 | ||||
| MATRix (4) > ASCT | CR | CR | 12 | ||||
| MATRix (4) | PD | PD | 0 | ||||
| R-MTX-ARAC (2) | PD | R-ITX-VP16 (4) | PD | PD | 0 | ||
| MATRix (4) > WBRT | CR | CR | 1 | ||||
| MATRix (4) > ASCT + IVT | CR | CR | 4 | ||||
| MATRix (4) > ASCT | CR | CR | 11 | ||||
| R-MTX-ARAC (2) | PD | PD | 0 | ||||
| R-MTX-ARAC (4) > ASCT | CR | CR | 11 | ||||
ARAC, high-dose cytarabine; De-VIC, dexamethasone, etoposide, ifosfamide, and carboplatin; ITT, intrathecal chemotherapy; ITX, high-dose ifosfamide; IVT, intravitreal therapy; MATRix, methotrexate, cytarabine, thiotepa, and rituximab; MPV, methotrexate, procarbazine and vincristine; MTX, high-dose methotrexate; R, rituximab; TMZ, temozolomide; VP16, etoposide.
*
Number in parentheses indicates number of chemotherapy courses.
†
Response to the last line of treatment before trial registration.
‡
TTP is the time to progression since the completion of the last line of treatment before trial registration.